Literature DB >> 31471058

The Role of Surgery in the Management of Prolactinomas.

Daniel A Donoho1, Edward R Laws2.   

Abstract

Prolactinomas are the most common functional pituitary adenoma. Many prolactinomas can be treated with medication, but all patients should be evaluated at a neuroendocrine center including experienced neurosurgeons trained in transsphenoidal surgery. Surgery for prolactinomas is feasible and can be performed with low morbidity. Patients never previously treated with dopamine agonists should be considered for surgery if they have neurologic deficits, pituitary apoplexy, an uncertain diagnosis, or a significantly cystic prolactinoma. Patients previously treated with dopamine agonists should be considered for surgery in cases of intolerance or resistance. Recurrent and aggressive prolactinomas often require multimodal therapy.
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Hyperprolactinemia; Pituitary; Prolactinoma; Surgery; Transsphenoidal

Mesh:

Substances:

Year:  2019        PMID: 31471058     DOI: 10.1016/j.nec.2019.05.010

Source DB:  PubMed          Journal:  Neurosurg Clin N Am        ISSN: 1042-3680            Impact factor:   2.509


  10 in total

Review 1.  Aggressive prolactinoma (Review).

Authors:  Ana Valea; Florica Sandru; Aida Petca; Mihai Cristian Dumitrascu; Mara Carsote; Razvan-Cosmin Petca; Adina Ghemigian
Journal:  Exp Ther Med       Date:  2021-11-24       Impact factor: 2.447

2.  Atypical Giant Suprasellar Prolactinoma Presenting With Visual Field Changes in the Absence of Symptoms of Hyperprolactinemia.

Authors:  Scott Sun; Jun Q Mo; Michael L Levy; John Crawford
Journal:  Cureus       Date:  2021-11-16

3.  Changes in the Options for Management of Prolactin Secreting Pituitary Adenomas.

Authors:  Sherry L Iuliano; Wenya Linda Bi; Edward R Laws
Journal:  J Neurol Surg B Skull Base       Date:  2021-02-18

4.  Extra-Pseudocapsular Transsphenoidal Surgery for Microprolactinoma in Women.

Authors:  Juan Chen; Xiang Guo; Zhuangzhuang Miao; Zhuo Zhang; Shengwen Liu; Xueyan Wan; Kai Shu; Yan Yang; Ting Lei
Journal:  J Clin Med       Date:  2022-07-05       Impact factor: 4.964

5.  Endoscopic, Endonasal Transsphenoidal Surgery for Tumors of the Sellar and Suprasellar Region: A Monocentric Historical Cohort Study of 369 Patients.

Authors:  Laura Van Gerven; Zhen Qian; Anastasiya Starovoyt; Mark Jorissen; Jeroen Meulemans; Johannes van Loon; Steven De Vleeschouwer; Julie Lambert; Marie Bex; Vincent Vander Poorten
Journal:  Front Oncol       Date:  2021-05-07       Impact factor: 6.244

6.  A scoping review to understand the indications, effectiveness, and limitations of cabergoline in radiological and biochemical remission of prolactinomas.

Authors:  Rakesh Mishra; Subhas K Konar; Adesh Shrivastava; Pradeep Chouksey; Sumit Raj; Amit Agrawal
Journal:  Indian J Endocrinol Metab       Date:  2022-02-17

7.  11C-methionine PET aids localization of microprolactinomas in patients with intolerance or resistance to dopamine agonist therapy.

Authors:  W A Bashari; M van der Meulen; J MacFarlane; D Gillett; R Senanayake; L Serban; A S Powlson; A M Brooke; D J Scoffings; J Jones; D G O'Donovan; J Tysome; T Santarius; N Donnelly; I Boros; F Aigbirhio; S Jefferies; H K Cheow; I A Mendichovszky; A G Kolias; R Mannion; O Koulouri; M Gurnell
Journal:  Pituitary       Date:  2022-05-24       Impact factor: 3.599

8.  Gamma Knife Radiosurgery (GKRS) for Patients with Prolactinomas: Long-Term Results From a Single-Center Experience.

Authors:  Yanli Li; Minyi Huang; Shunyao Liang; Chao Peng; Xi Li; Jiamin Zeng; Yong He; Wangen Li; Yinhui Deng; Jinxiu Yu
Journal:  Med Sci Monit       Date:  2020-09-23

9.  First-line surgery in prolactinomas: lessons from a long-term follow-up study in a tertiary referral center.

Authors:  L Andereggen; J Frey; R H Andres; M M Luedi; M El-Koussy; H R Widmer; J Beck; L Mariani; R W Seiler; E Christ
Journal:  J Endocrinol Invest       Date:  2021-04-13       Impact factor: 4.256

10.  Outcomes of transsphenoidal surgery in dopamine agonist-resistant prolactinomas: a retrospective study.

Authors:  Liguang Wei; Xialin Wei
Journal:  Hormones (Athens)       Date:  2021-07-18       Impact factor: 2.885

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.